p27/CDKN1B Cancer Research Results

p27/CDKN1B, p27kip1: Click to Expand ⟱
Source:
Type:
The cyclin-dependent kinase (Cdk) inhibitor p27 regulates cell proliferation, cell motility and apoptosis, and is inactivated through various means in many types of human cancer.

CDKN1B - Cyclin-Dependent Kinase Inhibitor 1B / p27

Abbreviation: CDKN1B, p27, p27Kip1

Type: Cyclin-dependent kinase inhibitor / cell-cycle regulator

Function: CDKN1B/p27 inhibits cyclin-CDK complexes, particularly cyclin E-CDK2 and cyclin A-CDK2, thereby restricting G1/S cell-cycle progression. It also regulates differentiation, transcription, cytoskeletal organization, cell migration, and cellular responses to growth-factor signaling.

Cancer: ↕ Context-dependent, but predominantly tumor-suppressive. Reduced nuclear p27 expression or functional loss can promote uncontrolled proliferation, tumor progression, and treatment resistance. However, cytoplasmic p27 can acquire CDK-independent pro-oncogenic functions that promote cell motility, invasion, and aggressive tumor behavior.
Nor, Normal Healthy: Click to Expand ⟱
Normal Healthy
Scientific Papers found: Click to Expand⟱
2686- BBR,    Effects of resveratrol, curcumin, berberine and other nutraceuticals on aging, cancer development, cancer stem cells and microRNAs
- Review, Nor, NA
Inflam↓, IL6↓, MCP1/CCL2↓, COX2↓, PGE2↓, MMP2↓, MMP9↓, DNAdam↑, eff↝, Telomerase↓, Bcl-2↓, AMPK↑, ROS↑, MMP↓, ATP↓, p‑mTORC1↓, p‑S6K↓, ERK↓, PI3K↓, PTEN↑, Akt↓, Raf↓, MEK↓, Dose↓, Dose↑, selectivity↑, TumCCA↑, eff↑, EGFR↓, Glycolysis↓, Dose?, p27/CDKN1B↑, CDK2↓, CDK4↓, cycD1/CCND1↓, cycE/CCNE↓, Bax:Bcl2↑, Casp3↑, Casp9↑, VEGFR2/KDR/Flk1↓, ChemoSen↑, eff↑, eff↑, PGE2↓, JAK2↓, STAT3↓, CXCR4↓, CCR7↓, uPA↓, CSCs↓, EMT↓, Diff↓, CD133↓, Nestin↓, n-MYC↓, NOTCH↓, SOX2↓, Hif1a↓, VEGF↓, RadioS↑,
7029- GA,    Gallic acid induces G1 phase arrest and apoptosis of triple-negative breast cancer cell MDA-MB-231 via p38 mitogen-activated protein kinase/p21/p27 axis
- in-vitro, BC, MDA-MB-231 - in-vitro, BC, HS587T - in-vitro, Nor, MCF10
AntiTum↑, tumCV↓, selectivity↑, TumCCA↑, cycD1/CCND1↓, CDK4↓, cycE/CCNE↓, CDK2↓, P21↑, p27/CDKN1B↑, Casp9↑, Casp3↑, ROS↑, mtDam↑, i-Ca+2↑, *ROS↓, *Apoptosis↓, TumCG↓,
1638- HCAs,    Anticancer potential of hydroxycinnamic acids: mechanisms, bioavailability, and therapeutic applications
- Review, Nor, NA
*BioAv↓, Inflam↓, COX2↓, TumCCA↑, ChemoSen↑, RadioS↑, selectivity↑, ROS↑, DNAdam↑, antiOx↑, SOD↑, Catalase↑, GPx↑, GSH↑, NRF2↑, NF-kB↓, Cyc↓, CDK1↑, P21↑, p27/CDKN1B↑, P53↑, VEGF↓, MAPK↓,

Showing Research Papers: 1 to 3 of 3

* indicates research on normal cells as opposed to diseased cells
Total Research Paper Matches: 3

Pathway results for Effect on Cancer / Diseased Cells:


Redox & Oxidative Stress(tgid=1) ⓘ

antiOx↑, 1,   Catalase↑, 1,   GPx↑, 1,   GSH↑, 1,   NRF2↑, 1,   ROS↑, 3,   SOD↑, 1,  

Mitochondria & Bioenergetics(tgid=3) ⓘ

ATP↓, 1,   MEK↓, 1,   MMP↓, 1,   mtDam↑, 1,   Raf↓, 1,  

Core Metabolism/Glycolysis(tgid=4) ⓘ

AMPK↑, 1,   Glycolysis↓, 1,   p‑S6K↓, 1,  

Cell Death(tgid=5) ⓘ

Akt↓, 1,   Bax:Bcl2↑, 1,   Bcl-2↓, 1,   Casp3↑, 2,   Casp9↑, 2,   MAPK↓, 1,   p27/CDKN1B↑, 3,   Telomerase↓, 1,  

Transcription & Epigenetics(tgid=7) ⓘ

tumCV↓, 1,  

DNA Damage & Repair(tgid=10) ⓘ

DNAdam↑, 2,   P53↑, 1,  

Cell Cycle & Senescence(tgid=11) ⓘ

CDK1↑, 1,   CDK2↓, 2,   CDK4↓, 2,   Cyc↓, 1,   cycD1/CCND1↓, 2,   cycE/CCNE↓, 2,   P21↑, 2,   TumCCA↑, 3,  

Proliferation, Differentiation & Cell State(tgid=12) ⓘ

CD133↓, 1,   CSCs↓, 1,   Diff↓, 1,   EMT↓, 1,   ERK↓, 1,   p‑mTORC1↓, 1,   n-MYC↓, 1,   Nestin↓, 1,   NOTCH↓, 1,   PI3K↓, 1,   PTEN↑, 1,   SOX2↓, 1,   STAT3↓, 1,   TumCG↓, 1,  

Migration(tgid=13) ⓘ

i-Ca+2↑, 1,   MMP2↓, 1,   MMP9↓, 1,   uPA↓, 1,  

Angiogenesis & Vasculature(tgid=14) ⓘ

EGFR↓, 1,   Hif1a↓, 1,   VEGF↓, 2,   VEGFR2/KDR/Flk1↓, 1,  

Immune & Inflammatory Signaling(tgid=16) ⓘ

CCR7↓, 1,   COX2↓, 2,   CXCR4↓, 1,   IL6↓, 1,   Inflam↓, 2,   JAK2↓, 1,   MCP1/CCL2↓, 1,   NF-kB↓, 1,   PGE2↓, 2,  

Drug Metabolism & Resistance(tgid=21) ⓘ

ChemoSen↑, 2,   Dose?, 1,   Dose↓, 1,   Dose↑, 1,   eff↑, 3,   eff↝, 1,   RadioS↑, 2,   selectivity↑, 3,  

Clinical Biomarkers(tgid=22) ⓘ

EGFR↓, 1,   IL6↓, 1,  

Functional Outcomes(tgid=23) ⓘ

AntiTum↑, 1,  
Total Targets: 76

Pathway results for Effect on Normal Cells:


Redox & Oxidative Stress(tgid=1) ⓘ

ROS↓, 1,  

Cell Death(tgid=5) ⓘ

Apoptosis↓, 1,  

Drug Metabolism & Resistance(tgid=21) ⓘ

BioAv↓, 1,  
Total Targets: 3

Scientific Paper Hit Count for: p27/CDKN1B, p27kip1
1 Berberine
1 Gallic acid
1 Hydroxycinnamic-acid
Query results interpretion may depend on "conditions" listed in the research papers.
Such Conditions may include : 
  -low or high Dose
  -format for product, such as nano of lipid formations
  -different cell line effects
  -synergies with other products 
  -if effect was for normal or cancerous cells

Filter Conditions: Pro/AntiFlg:%  IllCat:%  CanType:49  Cells:%  prod#:%  Target#:468  State#:%  Dir#:2
  wNotes=0  sortOrder:rid,rpid

 

Home Page